Retinoic acid [302-79-4]
Cat# HY-14649-100mg
Size : 100mg
Brand : MedChemExpress
Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.
For research use only. We do not sell to patients.
Retinoic acid Chemical Structure
CAS No. : 302-79-4
Size | Price | Stock | Quantity |
---|---|---|---|
Free Sample (0.1 - 0.5 mg) | Apply Now | ||
Solid + Solvent | |||
10 mM * 1 mL
in DMSO
ready for reconstitution
|
USD 66 | In-stock | |
Solution | |||
10 mM * 1 mL in DMSO | USD 66 | In-stock | |
Solid | |||
100 mg | USD 60 | In-stock | |
500 mg | USD 78 | In-stock | |
1 g | USD 96 | In-stock | |
5 g | Get quote | ||
10 g | Get quote |
* Please select Quantity before adding items.
This product is a controlled substance and not for sale in your territory.
Based on 53 publication(s) in Google Scholar
Other Forms of Retinoic acid:
- Retinoic acid (Standard) In-stock
- Retinoic acid-d5 In-stock
- Retinoic acid (GMP) Get quote
- 11-cis-Retinoic Acid-d5 Get quote
- Retinoic acid-d6 Get quote
- •Cell Res. 2022 Jun;32(6):513-529. [Abstract]
- •Blood. 2022 Aug 19;blood.2022015668. [Abstract]
- •Nat Commun. 2024 Jan 17;15(1):584. [Abstract]
- •Adv Sci (Weinh). 2022 Aug 28;e2203173. [Abstract]
- •Adv Sci (Weinh). 2022 Jan 22;e2105568. [Abstract]
- •Leukemia. 2023 Mar 28. [Abstract]
- •Biomaterials. 2023 Jan;292:121945. [Abstract]
- •EMBO Mol Med. 2022 Dec 13;e16373. [Abstract]
- •J Exp Clin Cancer Res. 2021 Apr 26;40(1):141. [Abstract]
- •Sci Adv. 2020 Nov 4;6(45):eaaz1410. [Abstract]
- •Cell Death Dis. 2023 Dec 7;14(12):802. [Abstract]
- •Cell Commun Signal. 2023 Jun 28;21(1):163. [Abstract]
- •Acta Pharmacol Sin. 2022 Nov 10. [Abstract]
- •Cell Death Dis. 2022 Jun 13;13(6):547. [Abstract]
- •Cancer Lett. 2020 Mar 31;473:130-138. [Abstract]
- •Eur J Med Chem. 2024 Mar 20:269:116344. [Abstract]
- •J Ginseng Res. 2023 Dec 27.
- •Phytother Res. 2023 Sep 11. [Abstract]
- •JCI Insight. 2023 Mar 28;e159058. [Abstract]
- •Cell Biosci. 2022 Nov 4;12(1):180. [Abstract]
- •Stem Cell Res Ther. 2022 Jul 18;13(1):324. [Abstract]
- •J Med Chem. 2022 Jan 21. [Abstract]
- •Blood Adv. 2021 Sep 14;5(17):3241-3253. [Abstract]
- •Bioeng Transl Med. 2021 Mar 27.
- •Life Sci. 2020 Feb 1;242:117247. [Abstract]
- •BBA-Mol Basis Dis. 2020 Jan 1;1866(1):165575. [Abstract]
- •J Gerontol A Biol Sci Med Sci. 2024 Jan 4:glad278. [Abstract]
- •Cancers (Basel). 2023 Oct 15, 15(20), 4995.
- •Drug Des Dev Ther. 2023 Feb 20.
- •Eur J Pharmacol. 2022 Feb 11;920:174822. [Abstract]
- •Clin Exp Dermatol. 2021 Dec 21. [Abstract]
- •Chem Biol Interact. 5 January 2022, 109740.
- •iScience. 2021 Oct 16;24(11):103296. [Abstract]
- •Eur J Pharmacol. 2019 May 15;851:174-185. [Abstract]
- •Gene. 2023 Sep 15;147806. [Abstract]
- •Exp Eye Res. 2023 Jul 6;109569. [Abstract]
- •Toxicol Lett. 17 June 2022.
- •Exp Ther Med. 2021 Feb 11.
- •Neurotox Res. 2020 Dec;38(4):859-870. [Abstract]
- •Fundam Clin Pharmacol. 2020 Jun;34(3):380-388. [Abstract]
- •PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- •Biochem Biophys Res Commun. 2019 May 28;513(2):386-391. [Abstract]
- •SSRN. 2024 Feb 14.
- •Research Square Preprint. 2023 Oct 12.
- •Research Square Preprint. 2023 Jun 12.
- •bioRxiv. 2023 Apr 14.
- •STAR Protoc. 2022 Oct 9;3(4):101740. [Abstract]
- •Research Square Print. 2022 Jul.
- •Intractable Rare Dis Res. 2019 May;8(2):113-119. [Abstract]
- •Oncotarget. 2017 Nov 22;8(65):109135-109150. [Abstract]
-
Retinoic acid purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 22;8(65):109135-109150. [Abstract]
- Cells are treated with RA (20 μM) plus ω-3 PUFAs (80 μM) with or without CQ (5 μM) for 24 h. Cell extracts are prepared and subjected to western blotting analysis.
-
Retinoic acid purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 22;8(65):109135-109150. [Abstract]
- MCF-7 cells are pretreated with the indicated chemical inhibitors for 30min, followed by 15 min treatment with RA (20 μM) + EPA (80 μM).Cell extracts are prepared and subjected to western blotting analysis.
-
Retinoic acid purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Nov 22;8(65):109135-109150. [Abstract]
- Cell morphology of MCF-7 treated with RA (20 μM)+ω-3 PUFAs (80 μM) with or without 3-MA (5 mM) for 24h.
•Related Screening Libraries:
•Related Small Molecules:
•Related Proteins:
View All PPAR Isoform Specific Products:
Biological Activity
Protocol
Purity & Documentation
References
Customer Review
Description |
Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[2][5] |
|
||||||||||||
In Vitro |
Retinoic acid (All-trans-retinoic acid, ATRA) is a highly potent derivative of vitamin A that is required for virtually all essential physiological processes and functions because of its involvement in transcriptional regulation of over 530 different genes. Retinoic acid exerts its actions by serving as an activating ligand of nuclear retinoic acid receptors (RARα-γ), which form heterodimers with retinoid X receptors (RXRα-γ)[1]. Retinoic acid (RA) bound to PPARα and PPARγ with a low affinity demonstrated by Kd values of 100-200 nM. In contrast, Retinoic acid associates with PPARβ/δ with a Kd of 17 nM, revealing both high affinity and isotype selectivity[2].Undifferentiated P19 cells express the Retinoic acid (RA) receptors RARα, RARβ, RARγ, and PPARβ/δ, as well as the Retinoic acid -binding proteins CRABP-II and FABP5. Induction of differentiation by treatment of cells with Retinoic acid results in transient up-regulation of CRABP-II and down-regulation of FABP5 that are observed at the level of both the respective proteins and mRNAs. Following the initial decrease, the level of both FABP5 protein and mRNA increases to attain a 2-2.5-fold higher level in mature neurons as compared with undifferentiated P19 cells. Induction of differentiation does not markedly affect the levels of either RARα or PPARβ/δ. The level of RARγ mRNA decreases by about 5-fold by day 4 and remained low in mature neurons[3].Retinoic acid (RA) is a morphogen derived from retinol (vitamin A) that plays important roles in cell growth, differentiation, and organogenesis. The Retinoic acid interacts with retinoic acid receptor (RAR) and retinoic acid X receptor (RXR) which then regulate the target gene expression[4]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Clinical Trial |
|
||||||||||||
Molecular Weight |
300.44 |
||||||||||||
Formula |
C20H28O2 |
||||||||||||
CAS No. | |||||||||||||
Appearance |
Solid |
||||||||||||
Color |
Light yellow to yellow |
||||||||||||
SMILES |
CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)=C(C)CCC1 |
||||||||||||
Structure Classification | |||||||||||||
Initial Source | |||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Storage |
-20°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
||||||||||||
Solvent & Solubility |
In Vitro:
DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
For the following dissolution methods, please prepare the working solution directly.
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Purity & Documentation | |||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO | 1 mM | 3.3285 mL | 16.6423 mL | 33.2845 mL | 83.2113 mL |
5 mM | 0.6657 mL | 3.3285 mL | 6.6569 mL | 16.6423 mL | |
10 mM | 0.3328 mL | 1.6642 mL | 3.3285 mL | 8.3211 mL | |
15 mM | 0.2219 mL | 1.1095 mL | 2.2190 mL | 5.5474 mL | |
20 mM | 0.1664 mL | 0.8321 mL | 1.6642 mL | 4.1606 mL | |
25 mM | 0.1331 mL | 0.6657 mL | 1.3314 mL | 3.3285 mL | |
30 mM | 0.1109 mL | 0.5547 mL | 1.1095 mL | 2.7737 mL | |
40 mM | 0.0832 mL | 0.4161 mL | 0.8321 mL | 2.0803 mL | |
50 mM | 0.0666 mL | 0.3328 mL | 0.6657 mL | 1.6642 mL | |
60 mM | 0.0555 mL | 0.2774 mL | 0.5547 mL | 1.3869 mL | |
80 mM | 0.0416 mL | 0.2080 mL | 0.4161 mL | 1.0401 mL | |
100 mM | 0.0333 mL | 0.1664 mL | 0.3328 mL | 0.8321 mL |
Retinoic acid Related Classifications
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Bulk Inquiry
Inquiry Information
- Product Name:
- Retinoic acid
- Cat. No.:
- HY-14649
- Quantity:
- MCE Japan Authorized Agent: